Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo-controlled trial to evaluate the effects of adjunctive treatment with Aripiprazole on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine

Next Previous
Trial Profile

Randomized, double-blind, placebo-controlled trial to evaluate the effects of adjunctive treatment with Aripiprazole on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Clozapine
  • Indications Metabolic syndrome; Psychotic disorders; Weight gain
  • Focus Therapeutic Use

Most Recent Events

  • 12 Sep 2016 Status changed from not yet recruiting to recruiting.
  • 13 Mar 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top